Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study

Next Previous
Trial Profile

Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Somatropin (Primary)
  • Indications Dwarfism; Growth disorders; Prader-Willi syndrome; Short stature; Somatotropin deficiency; Turner's syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PATRO Children

Most Recent Events

  • 01 Jun 2022 Results of an analysis compared the safety and effectiveness data from patients treated with recombinant human growth hormone (rhGH) in the USA versus other countries published in the European Journal of Pediatrics
  • 03 Jul 2020 New trial record
  • 15 Jun 2020 Results published in the Journal of Endocrinological Investigation

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top